Immunoglobulin A nephropathy

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

5FDA treatments

9Recruiting trials

Regulatory Watchboard

10 events

Oct 2026Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Novartis Pharmaceuticals — PHASE3

TrialNOT YET RECRUITING

Mar 2026A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Hinge Bio — PHASE1

TrialRECRUITING

Dec 2025Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Regeneron Pharmaceuticals — PHASE1

TrialRECRUITING

Oct 2025Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study

Radboud University Medical Center — PHASE2, PHASE3

TrialRECRUITING

Aug 2025A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

Shanghai Henlius Biotech — PHASE2

TrialRECRUITING

Jul 2025Study of BHV-1400 in IgA Nephropathy

Biohaven Therapeutics Ltd. — PHASE1

TrialRECRUITING

Jun 2025Study of Ravulizumab in Pediatric Participants With Primary IgAN

Alexion Pharmaceuticals, Inc. — PHASE3

TrialRECRUITING

Feb 2025Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Novartis Pharmaceuticals — PHASE2

TrialRECRUITING

Feb 2025Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Christian Medical College, Vellore, India — PHASE4

TrialRECRUITING

Sep 2024

Filspari: FDA approved

to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

Patient Assistance Programs2

FABHALTA

Novartis Pharmaceuticals Corporation

OpenContact for detailsApply ↗

Vanrafia

Novartis

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

5 FDA-approved

Filspari

(sparsentan)Orphan drug

Travere Therapeutics

Endothelin Receptor Antagonist [EPC]

12.1 Mechanism of Action Sparsentan is a single molecule with antagonism of the endothelin type A receptor (ET A R) and the angiotensin II type 1 rece...

Approved Sep 2024FDA label ↗

FABHALTA

(IPTACOPAN)Orphan drugaccelerated

Novartis Pharmaceuticals Corporation

Approved Aug 2024FDA label ↗

Vanrafia

(atrasentan)Orphan drugaccelerated

Novartis

12.1 Mechanism of Action Atrasentan is an ET A receptor antagonist (Ki = 0.034 nM) with >1800-fold selectivity for the ET A receptor compared to the e...

Tarpeyo

(budesonide delayed-release)Orphan drugstandard

Calliditas Therapeutics

Corticosteroid [EPC]

12.1 Mechanism of Action Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substan...

Voyxact

(sibeprenlimab)Orphan drugaccelerated

Otsuka

12.1 Mechanism of Action VOYXACT binds to APRIL with a dissociation constant (K D ) of 0.95 pM, which blocks signaling at the B cell maturation antige...

View full treatment details on disease page →

Clinical Trial Landscape

9 active trials

5Phase 3

1Phase 4

1Phase 2

1Phase 1

1PHASE2, PHASE3

9Total recruiting

Search clinical trials for Immunoglobulin A nephropathy →

Recent News & Research

1 article

FDASep 15, 2025

Filspari Approved for IgA Nephropathy

The FDA approved Filspari (sparsentan), a dual endothelin and angiotensin receptor antagonist, for IgA nephropathy at risk of disease progression.

Browse all Immunoglobulin A nephropathy news →

Specialist Network

Top 6 by expertise

Eric Jonasch, MD, M.D

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 3412 trials

Jicheng Lv

Peking University First Hospital

Score 342 trials

Fangjian Zhou, Professor

Director of Dept. of Urology, Sun Yat-sen University Cancer Center

Score 112 trials

Fernando Fervenza, MD, PhD, M.D

Mayo Clinic

📍 ROCHESTER, MN

Score 62 trials

Nawel Bourayou, MD

Incyte Corporation

Score 32 trials

Vladimir Dobronravov, Professor, MD, PhD, DMedSci

St. Petersburg State Pavlov Medical University

View all Immunoglobulin A nephropathy specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles